首页> 外文学位 >Risk factors for clinical manifestation in carriers of Factor V Leiden and prothrombin gene mutations.
【24h】

Risk factors for clinical manifestation in carriers of Factor V Leiden and prothrombin gene mutations.

机译:因子V Leiden和凝血酶原基因突变携带者临床表现的危险因素。

获取原文
获取原文并翻译 | 示例

摘要

Background. Carriers of Factor V Leiden (FVL) and prothrombin G20210A gene mutations (PGM) have an increased risk of developing thromboembolic events and adverse outcomes of pregnancy.;Objective. To identify risk factors which may predispose carriers of FVL and/or PGM to develop thromboembolic events and adverse outcomes of pregnancy.;Methods. Retrospective case control study of 217 carriers of FVL and/or PGM at two tertiary centers between January 2000 and December 2006. Symptomatic carriers (cases) were compared with asymptomatic carriers (controls) for the following risk factors: environmental, cardiovascular, family history of thrombosis and presence of other thrombophilias. For female carriers, we included the use of female hormones, pregnancy, and the post-partum period.;Results. Of the 217 carriers, there were 155 (71%) cases and 62 (29%) controls. Of the 155 cases, 90 (58%) had venous thrombosis and 26 (17%) arterial thrombosis. Among the 123 symptomatic female carriers, 55 (45%) had recurrent pregnancy losses, and 9 (7%) other adverse outcomes of pregnancy. The postoperative state and the presence of antiphospholipid antibodies (aPLAs) were risk factors for thromboembolic events and adverse outcomes of pregnancy in 10 (6%) and 22 (13%) cases, respectively. The presence of aPLAs in symptomatic carriers increased the risk of developing thromboembolic events 4.4-fold.;Conclusions. The postoperative state and the presence of aPLAs were significant risk factors for thromboembolic events and adverse outcomes of pregnancy among FVL and/or PGM carriers. Testing for the presence of aPLAs may be warranted in FVL and/or PGM carriers who develop these adverse clinical manifestations.;Key words. case-control study; hereditary thrombophilia FVL; PGM, risk factors; aPLAs; venous thrombosis; arterial thrombosis; recurrent pregnancy loss.
机译:背景。因子V莱顿(FVL)和凝血酶原G20210A基因突变(PGM)的携带者发生血栓栓塞事件和妊娠不良后果的风险增加。鉴定可能导致FVL和/或PGM携带者发生血栓栓塞事件和妊娠不良后果的危险因素。在2000年1月至2006年12月期间对两个三级中心的217例FVL和/或PGM携带者进行了回顾性病例对照研究。比较了有症状的携带者(病例)和无症状的携带者(对照)的以下危险因素:环境,心血管病,家族史血栓形成和其他血栓形成倾向。对于女性携带者,我们包括女性荷尔蒙的使用,怀孕和产后时期。在217名携带者中,有155名(71%)病例和62名(29%)对照。在155例病例中,有90例(58%)患有静脉血栓形成,而26例(17%)患有动脉血栓形成。在123例有症状的女性携带者中,55例(45%)复发性流产,9例(7%)其他不良妊娠结局。术后状态和抗磷脂抗体(aPLAs)的存在分别是10例(6%)和22例(13%)的血栓栓塞事件和妊娠不良结局的危险因素。有症状的携带者中存在aPLAs,使发生血栓栓塞事件的风险增加了4.4倍。 FVL和/或PGM携带者的血栓栓塞事件和妊娠不良结局是术后状态和存在aPLAs的重要危险因素。在出现这些不良临床表现的FVL和/或PGM携带者中可能需要测试aPLAs的存在。病例对照研究;遗传性血栓形成性FVL; PGM,危险因素;协议书;静脉血栓形成;动脉血栓形成反复流产。

著录项

  • 作者

    De Sancho, Maria.;

  • 作者单位

    Weill Medical College of Cornell University.;

  • 授予单位 Weill Medical College of Cornell University.;
  • 学科 Genetics.;Molecular biology.;Obstetrics.
  • 学位 M.S.
  • 年度 2009
  • 页码 21 p.
  • 总页数 21
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号